{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:37:19Z","timestamp":1786664239921,"version":"build-2736575974"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Charles University in Prague, Czech Republic","award":["Cooperatio Program"],"award-info":[{"award-number":["Cooperatio Program"]}]},{"name":"Charles University in Prague, Czech Republic","award":["research area NEUR"],"award-info":[{"award-number":["research area NEUR"]}]},{"name":"grant projects of the Ministry of Health of the Czech Republic","award":["FN HK 00179906"],"award-info":[{"award-number":["FN HK 00179906"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40268-023-00434-6","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T18:02:31Z","timestamp":1693245751000},"page":"331-338","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing\u2013Remitting and Secondary Progressive Multiple Sclerosis"],"prefix":"10.1007","volume":"23","author":[{"given":"Martin","family":"Vali\u0161","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Achiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Mare\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Tich\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"\u0160toura\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Haluskov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Angelucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1772-8781","authenticated-orcid":false,"given":"Zby\u0161ek","family":"Pavelek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"key":"434_CR1","first-page":"1","volume":"19","author":"N Ghasemi","year":"2017","unstructured":"Ghasemi N, Razavi S, Nikzad E. Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy. Cell J. 2017;19:1\u201310.","journal-title":"Cell J"},{"key":"434_CR2","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA, Cutter GR, S\u00f8rensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278\u201386.","journal-title":"Neurology"},{"key":"434_CR3","doi-asserted-by":"crossref","unstructured":"Attfield KE, Jensen LT, Kaufmann M, Friese MA, Fugger L. The immunology of multiple sclerosis. Nat Rev Immunol [Internet]. 2022. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35508809.","DOI":"10.1038\/s41577-022-00718-z"},{"key":"434_CR4","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1212\/WNL.0000000000009636","volume":"94","author":"FD Lublin","year":"2020","unstructured":"Lublin FD, Coetzee T, Cohen JA, Marrie RA, Thompson AJ, International Advisory Committee on Clinical Trials in MS. The 2013 clinical course descriptors for multiple sclerosis: a clarification. Neurology. 2020;94:1088\u201392.","journal-title":"Neurology"},{"key":"434_CR5","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","volume":"9","author":"H Lassmann","year":"2018","unstructured":"Lassmann H. Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol. 2018;9:3116.","journal-title":"Front Immunol"},{"key":"434_CR6","unstructured":"Iaffaldano P, Lucisano G, Guerra T, Patti F, Onofrj M, Brescia Morra V, et al. Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: a study from the Italian MS Register. Mult Scler [Internet]. 2022;13524585221114008. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35971322."},{"key":"434_CR7","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S1474-4422(14)70305-9","volume":"14","author":"B Hemmer","year":"2015","unstructured":"Hemmer B, Kerschensteiner M, Korn T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol. 2015;14:406\u201319.","journal-title":"Lancet Neurol"},{"key":"434_CR8","doi-asserted-by":"crossref","unstructured":"Macaron G, Ontaneda D. Diagnosis and management of progressive multiple sclerosis. Biomedicines [Internet]. 2019;7:56. Available from: https:\/\/www.mdpi.com\/2227-9059\/7\/3\/56.","DOI":"10.3390\/biomedicines7030056"},{"key":"434_CR9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162\u201373.","journal-title":"Lancet Neurol"},{"key":"434_CR10","doi-asserted-by":"crossref","unstructured":"Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol [Internet]. 2012;8:647\u201356. Available from: https:\/\/www.nature.com\/articles\/nrneurol.2012.168.","DOI":"10.1038\/nrneurol.2012.168"},{"key":"434_CR11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/nutrit\/nux036","volume":"75","author":"JL Kaczmarek","year":"2017","unstructured":"Kaczmarek JL, Thompson SV, Holscher HD. Complex interactions of circadian rhythms, eating behaviors, and the gastrointestinal microbiota and their potential impact on health. Nutr Rev. 2017;75:673\u201382. https:\/\/doi.org\/10.1093\/nutrit\/nux036.","journal-title":"Nutr Rev"},{"key":"434_CR12","first-page":"s159","volume":"22","author":"FM Hart","year":"2016","unstructured":"Hart FM, Bainbridge J. Current and emerging treatment of multiple sclerosis. Am J Manag Care. 2016;22:s159\u201370.","journal-title":"Am J Manag Care"},{"issue":"1","key":"434_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1055\/s-0033-1343794","volume":"33","author":"MA Willis","year":"2013","unstructured":"Willis MA, Cohen JA. Fingolimod therapy for multiple sclerosis. Semin Neurol. 2013;33(1):37\u201344.","journal-title":"Semin Neurol"},{"key":"434_CR14","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1080\/13543784.2019.1676725","volume":"28","author":"AD Goodman","year":"2019","unstructured":"Goodman AD, Anadani N, Gerwitz L. Siponimod in the treatment of multiple sclerosis. Expert Opin Investig Drugs. 2019;28:1051\u20137.","journal-title":"Expert Opin Investig Drugs"},{"key":"434_CR15","unstructured":"No Title. p. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/ma."},{"key":"434_CR16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pharmthera.2017.11.001","volume":"185","author":"A Huwiler","year":"2018","unstructured":"Huwiler A, Zangemeister-Wittke U. The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: recent findings and new perspectives. Pharmacol Ther. 2018;185:34\u201349.","journal-title":"Pharmacol Ther"},{"key":"434_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228380","volume":"15","author":"M Hjorth","year":"2020","unstructured":"Hjorth M, Dandu N, Mellerg\u00e5rd J. Treatment effects of fingolimod in multiple sclerosis: selective changes in peripheral blood lymphocyte subsets. Kim CH, editor. PLoS ONE. 2020;15: e0228380. https:\/\/doi.org\/10.1371\/journal.pone.0228380.","journal-title":"PLoS ONE"},{"key":"434_CR18","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s40265-014-0264-y","volume":"74","author":"M Sanford","year":"2014","unstructured":"Sanford M. Fingolimod: a review of its use in relapsing\u2013remitting multiple sclerosis. Drugs. 2014;74:1411\u201333.","journal-title":"Drugs"},{"key":"434_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.07.011","volume":"36","author":"J Haas","year":"2019","unstructured":"Haas J, Jeffery D, Silva D, Meier DP, Meinert R, Cohen J, et al. Early initiation of fingolimod reduces the rate of severe relapses over the long term: post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies. Mult Scler Relat Disord. 2019;36: 101335.","journal-title":"Mult Scler Relat Disord."},{"key":"434_CR20","doi-asserted-by":"crossref","unstructured":"Kleiter I, Ayzenberg I, Hoepner R. Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations. Ther Clin Risk Manag. 2016;261. Available from: https:\/\/www.dovepress.com\/fingolimod-for-multiple-sclerosis-and-emerging-indications-appropriate-peer-reviewed-article-TCRM.","DOI":"10.2147\/TCRM.S65558"},{"key":"434_CR21","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1007\/s40265-017-0814-1","volume":"77","author":"G Comi","year":"2017","unstructured":"Comi G, Hartung H-P, Bakshi R, Williams IM, Wiendl H. Benefit-risk profile of sphingosine-1-phosphate receptor modulators in relapsing and secondary progressive multiple sclerosis. Drugs. 2017;77:1755\u201368.","journal-title":"Drugs"},{"key":"434_CR22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40265-020-01431-8","volume":"81","author":"J Chun","year":"2021","unstructured":"Chun J, Giovannoni G, Hunter SF. Sphingosine 1-phosphate receptor modulator therapy for multiple sclerosis: differential downstream receptor signalling and clinical profile effects. Drugs. 2021;81:207\u201331.","journal-title":"Drugs"},{"key":"434_CR23","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(15)01314-8","volume":"387","author":"F Lublin","year":"2016","unstructured":"Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2016;387:1075\u201384.","journal-title":"Lancet (London, England)."},{"key":"434_CR24","doi-asserted-by":"publisher","first-page":"e869","DOI":"10.1212\/WNL.0000000000012354","volume":"97","author":"I Roos","year":"2021","unstructured":"Roos I, Leray E, Casey R, Horakova D, Havrdova E, Izquierdo G, et al. Effects of high- and low-efficacy therapy in secondary progressive multiple sclerosis. Neurology. 2021;97:e869\u201380. https:\/\/doi.org\/10.1212\/WNL.0000000000012354.","journal-title":"Neurology"},{"key":"434_CR25","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1177\/1352458511400476","volume":"17","author":"S Al-Izki","year":"2011","unstructured":"Al-Izki S, Pryce G, Jackson SJ, Giovannoni G, Baker D. Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis. Mult Scler J. 2011;17:939\u201348. https:\/\/doi.org\/10.1177\/1352458511400476.","journal-title":"Mult Scler J"},{"key":"434_CR26","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/ana.22426","volume":"69","author":"JA Cohen","year":"2011","unstructured":"Cohen JA, Chun J. Mechanisms of fingolimod\u2019s efficacy and adverse effects in multiple sclerosis. Ann Neurol. 2011;69:759\u201377. https:\/\/doi.org\/10.1002\/ana.22426.","journal-title":"Ann Neurol"},{"key":"434_CR27","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1111\/ene.13694","volume":"25","author":"J Frau","year":"2018","unstructured":"Frau J, Sormani MP, Signori A, Realmuto S, Baroncini D, Annovazzi P, et al. Clinical activity after fingolimod cessation: disease reactivation or rebound? Eur J Neurol. 2018;25:1270\u20135.","journal-title":"Eur J Neurol"},{"key":"434_CR28","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.pjnns.2017.10.001","volume":"52","author":"T Litwin","year":"2018","unstructured":"Litwin T, Smoli\u0144ski \u0141, Cz\u0142onkowka A. Substantial disease exacerbation in a patient with relapsing\u2013remitting multiple sclerosis after withdrawal from siponimod. Neurol Neurochir Pol. 2018;52:98\u2013101.","journal-title":"Neurol Neurochir Pol"},{"key":"434_CR29","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s40265-019-01140-x","volume":"79","author":"ZT Al-Salama","year":"2019","unstructured":"Al-Salama ZT. Siponimod: first global approval. Drugs. 2019;79:1009\u201315. https:\/\/doi.org\/10.1007\/s40265-019-01140-x.","journal-title":"Drugs"},{"key":"434_CR30","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s40263-020-00771-z","volume":"34","author":"LJ Scott","year":"2020","unstructured":"Scott LJ. Siponimod: a review in secondary progressive multiple sclerosis. CNS Drugs. 2020;34:1191\u2013200. https:\/\/doi.org\/10.1007\/s40263-020-00771-z.","journal-title":"CNS Drugs"},{"key":"434_CR31","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391:1263\u201373.","journal-title":"Lancet"},{"key":"434_CR32","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/S1474-4422(13)70102-9","volume":"12","author":"K Selmaj","year":"2013","unstructured":"Selmaj K, Li DKB, Hartung H-P, Hemmer B, Kappos L, Freedman MS, et al. Siponimod for patients with relapsing\u2013remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013;12:756\u201367.","journal-title":"Lancet Neurol"},{"key":"434_CR33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40263-021-00798-w","volume":"35","author":"R Roy","year":"2021","unstructured":"Roy R, Alotaibi AA, Freedman MS. Sphingosine 1-phosphate receptor modulators for multiple sclerosis. CNS Drugs. 2021;35:385\u2013402.","journal-title":"CNS Drugs"},{"key":"434_CR34","doi-asserted-by":"crossref","unstructured":"Kipp M. Does siponimod exert direct effects in the central nervous system? Cells [Internet]. 2020;9:1771. Available from: https:\/\/www.mdpi.com\/2073-4409\/9\/8\/1771.","DOI":"10.3390\/cells9081771"},{"key":"434_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12974-016-0686-4","volume":"13","author":"A Gentile","year":"2016","unstructured":"Gentile A, Musella A, Bullitta S, Fresegna D, De Vito F, Fantozzi R, et al. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis. J Neuroinflammation. 2016;13:207. https:\/\/doi.org\/10.1186\/s12974-016-0686-4.","journal-title":"J Neuroinflammation"},{"key":"434_CR36","doi-asserted-by":"crossref","unstructured":"Dietrich M, Hecker C, Martin E, Langui D, Gliem M, Stankoff B, et al. Increased remyelination and proregenerative microglia under siponimod therapy in mechanistic models. Neurol Neuroimmunol Neuroinflamm [Internet]. 2022;9. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35354603.","DOI":"10.1212\/NXI.0000000000001161"},{"key":"434_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00635\/full","author":"E Colombo","year":"2020","unstructured":"Colombo E, Bassani C, De Angelis A, Ruffini F, Ottoboni L, Comi G, et al. Siponimod (BAF312) activates Nrf2 while hampering NF\u03baB in human astrocytes, and protects from astrocyte-induced neurodegeneration. Front Immunol. 2020. https:\/\/doi.org\/10.3389\/fimmu.2020.00635\/full.","journal-title":"Front Immunol"},{"key":"434_CR38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12974-016-0494-x","volume":"13","author":"C O\u2019Sullivan","year":"2016","unstructured":"O\u2019Sullivan C, Schubart A, Mir AK, Dev KK. The dual S1PR1\/S1PR5 drug BAF312 (siponimod) attenuates demyelination in organotypic slice cultures. J Neuroinflammation. 2016;13:31.","journal-title":"J Neuroinflammation"},{"key":"434_CR39","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1177\/1352458517721355","volume":"24","author":"A Mannioui","year":"2018","unstructured":"Mannioui A, Vauzanges Q, Fini JB, Henriet E, Sekizar S, Azoyan L, et al. The Xenopus tadpole: an in vivo model to screen drugs favoring remyelination. Mult Scler J. 2018;24:1421\u201332. https:\/\/doi.org\/10.1177\/1352458517721355.","journal-title":"Mult Scler J"},{"key":"434_CR40","first-page":"CD013647","volume":"11","author":"L Cao","year":"2021","unstructured":"Cao L, Li M, Yao L, Yan P, Wang X, Yang Z, et al. Siponimod for multiple sclerosis. Cochrane database Syst Rev. 2021;11:CD013647.","journal-title":"Cochrane database Syst Rev"},{"key":"434_CR41","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1080\/03007995.2021.1968362","volume":"37","author":"IA Samjoo","year":"2021","unstructured":"Samjoo IA, Worthington E, Haltner A, Spin P, Drudge C, Cameron C, et al. Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses. Curr Med Res Opin. 2021;37:1933\u201344.","journal-title":"Curr Med Res Opin"},{"key":"434_CR42","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1001\/jamaneurol.2016.1451","volume":"73","author":"L Kappos","year":"2016","unstructured":"Kappos L, Li DKB, St\u00fcve O, Hartung H-P, Freedman MS, Hemmer B, et al. Safety and efficacy of siponimod (BAF312) in patients with relapsing\u2013remitting multiple sclerosis: dose-blinded, randomized extension of the phase 2 BOLD study. JAMA Neurol. 2016;73:1089\u201398.","journal-title":"JAMA Neurol"},{"key":"434_CR43","doi-asserted-by":"publisher","first-page":"175628642211468","DOI":"10.1177\/17562864221146836","volume":"16","author":"A Bayas","year":"2023","unstructured":"Bayas A, Christ M, Faissner S, Klehmet J, Pul R, Skripuletz T, et al. Disease-modifying therapies for relapsing\/active secondary progressive multiple sclerosis\u2014a review of population-specific evidence from randomized clinical trials. Ther Adv Neurol Disord. 2023;16:17562864221146836.","journal-title":"Ther Adv Neurol Disord"},{"key":"434_CR44","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1007\/s10072-022-05988-y","volume":"43","author":"S Yang","year":"2022","unstructured":"Yang S, Li X, Wang J, Wang T, Xu Z, Gao H, et al. Sphingosine-1-phosphate receptor modulators versus interferon beta for the treatment of relapsing\u2013remitting multiple sclerosis: findings from randomized controlled trials. Neurol Sci. 2022;43:3565\u201381.","journal-title":"Neurol Sci"},{"key":"434_CR45","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s40273-021-01023-8","volume":"39","author":"N Schur","year":"2021","unstructured":"Schur N, Gudala K, Vudumula U, Vadapalle S, Bhadhuri A, Casanova A, et al. Cost effectiveness and budget impact of siponimod compared to interferon beta-1a in the treatment of adult patients with secondary progressive multiple sclerosis with active disease in Switzerland. Pharmacoeconomics. 2021;39:563\u201377.","journal-title":"Pharmacoeconomics"},{"key":"434_CR46","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1080\/13696998.2022.2078103","volume":"25","author":"S Montgomery","year":"2022","unstructured":"Montgomery S, Woodhouse F, Vudumula U, Gudala K, Duddy M, Kroes M. Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK. J Med Econ. 2022;25:669\u201378.","journal-title":"J Med Econ"},{"key":"434_CR47","doi-asserted-by":"publisher","first-page":"100346","DOI":"10.1016\/j.ensci.2021.100346","volume":"23","author":"K Senzaki","year":"2021","unstructured":"Senzaki K, Ochi H, Ochi M, Okada Y, Miura S, Ohyagi Y. Disease reactivation in a patient with secondary progressive multiple sclerosis after switching treatment from fingolimod to siponimod. eNeurologicalSci. 2021;23:100346.","journal-title":"eNeurologicalSci."},{"key":"434_CR48","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s00415-015-7999-6","volume":"263","author":"R Hussain","year":"2016","unstructured":"Hussain R, O\u2019Leary S, Pacheco FM, Zacharias TE, Litvak P, Sguigna P, et al. Acute relapse after initiation of siponimod in a patient with secondary progressive MS. J Neurol. 2016;263:606\u201310.","journal-title":"J Neurol"},{"key":"434_CR49","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.1007\/s10072-021-05546-y","volume":"42","author":"M Sparaco","year":"2021","unstructured":"Sparaco M, Miele G, Bonavita S. Severe lymphopenia switching from fingolimod to siponimod. Neurol Sci. 2021;42:4837\u20138.","journal-title":"Neurol Sci"},{"key":"434_CR50","doi-asserted-by":"crossref","unstructured":"Abbadessa G, Maida E, Miele G, Bile F, Lavorgna L, Bonavita S. Disease reactivation in secondary progressive multiple sclerosis patients switching from fingolimod to siponimod: a case series. J Clin Med [Internet]. 2022;11. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36294354.","DOI":"10.3390\/jcm11206033"},{"key":"434_CR51","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/glia.21021","volume":"58","author":"R Van Doorn","year":"2010","unstructured":"Van Doorn R, Van Horssen J, Verzijl D, Witte M, Ronken E, Van Het Hof B, et al. Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. Glia. 2010;58:1465\u201376.","journal-title":"Glia"},{"key":"434_CR52","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrm.2017.107","volume":"19","author":"YA Hannun","year":"2018","unstructured":"Hannun YA, Obeid LM. Sphingolipids and their metabolism in physiology and disease. Nat Rev Mol Cell Biol. 2018;19:175\u201391.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"434_CR53","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/MOL.0000000000000825","volume":"33","author":"P Therond","year":"2022","unstructured":"Therond P, Chapman MJ. Sphingosine-1-phosphate: metabolism, transport, atheroprotection and effect of statin treatment. Curr Opin Lipidol. 2022;33:199\u2013207.","journal-title":"Curr Opin Lipidol"},{"key":"434_CR54","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.neuropharm.2016.11.006","volume":"113","author":"S O\u2019Sullivan","year":"2017","unstructured":"O\u2019Sullivan S, Dev KK. Sphingosine-1-phosphate receptor therapies: advances in clinical trials for CNS-related diseases. Neuropharmacology. 2017;113:597\u2013607.","journal-title":"Neuropharmacology"},{"key":"434_CR55","doi-asserted-by":"crossref","unstructured":"Roggeri A, Schepers M, Tiane A, Rombaut B, van Veggel L, Hellings N, et al. Sphingosine-1-phosphate receptor modulators and oligodendroglial cells: beyond immunomodulation. Int J Mol Sci [Internet]. 2020;21. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33066042.","DOI":"10.3390\/ijms21207537"},{"key":"434_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114465","volume":"186","author":"SF Spampinato","year":"2021","unstructured":"Spampinato SF, Merlo S, Sano Y, Kanda T, Sortino MA. Protective effect of the sphingosine-1 phosphate receptor agonist siponimod on disrupted blood brain barrier function. Biochem Pharmacol. 2021;186: 114465.","journal-title":"Biochem Pharmacol"},{"key":"434_CR57","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.4103\/1673-5374.259622","volume":"14","author":"P Hundehege","year":"2019","unstructured":"Hundehege P, Cerina M, Eichler S, Thomas C, Herrmann AM, G\u00f6bel K, et al. The next-generation sphingosine-1 receptor modulator BAF312 (siponimod) improves cortical network functionality in focal autoimmune encephalomyelitis. Neural Regen Res. 2019;14:1950\u201360.","journal-title":"Neural Regen Res"},{"key":"434_CR58","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1124\/mol.115.100222","volume":"89","author":"MG Sanna","year":"2016","unstructured":"Sanna MG, Vincent KP, Repetto E, Nguyen N, Brown SJ, Abgaryan L, et al. Bitopic sphingosine 1-phosphate receptor 3 (S1P3) antagonist rescue from complete heart block: pharmacological and genetic evidence for direct S1P3 regulation of mouse cardiac conduction. Mol Pharmacol. 2016;89:176\u201386.","journal-title":"Mol Pharmacol"},{"key":"434_CR59","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.2147\/DDDT.S122249","volume":"11","author":"A Gajofatto","year":"2017","unstructured":"Gajofatto A. Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date. Drug Des Dev Ther. 2017;11:3153\u20137.","journal-title":"Drug Des Dev Ther"},{"key":"434_CR60","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1111\/jcmm.12549","volume":"19","author":"EE Egom","year":"2015","unstructured":"Egom EE, Kruzliak P, Rotrekl V, Lei M. The effect of the sphingosine-1-phosphate analogue FTY720 on atrioventricular nodal tissue. J Cell Mol Med. 2015;19:1729\u201334.","journal-title":"J Cell Mol Med"},{"key":"434_CR61","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1212\/CPJ.0000000000000027","volume":"4","author":"S Cugati","year":"2014","unstructured":"Cugati S, Chen CS, Lake S, Lee AW. Fingolimod and macular edema: pathophysiology, diagnosis, and management. Neurol Clin Pract. 2014;4:402\u20139. https:\/\/doi.org\/10.1212\/CPJ.0000000000000027.","journal-title":"Neurol Clin Pract."},{"key":"434_CR62","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13643-021-01782-7","volume":"10","author":"J Mu\u00f1oz-Ortiz","year":"2021","unstructured":"Mu\u00f1oz-Ortiz J, Reyes-Guanes J, Zapata-Bravo E, Mora-Mu\u00f1oz L, Reyes-Hurtado JA, Tierradentro-Garc\u00eda LO, et al. Ocular adverse events from pharmacological treatment in patients with multiple sclerosis\u2014a systematic review of the literature. Syst Rev. 2021;10:280.","journal-title":"Syst Rev"},{"key":"434_CR63","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s13311-017-0565-4","volume":"14","author":"BZ Chaudhry","year":"2017","unstructured":"Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. Neurotherapeutics. 2017;14:859\u201373.","journal-title":"Neurotherapeutics"},{"key":"434_CR64","first-page":"205521732110491","volume":"7","author":"M Bigaud","year":"2021","unstructured":"Bigaud M, Rudolph B, Briard E, Beerli C, Hofmann A, Hermes E, et al. Siponimod (BAF312) penetrates, distributes, and acts in the central nervous system: preclinical insights. Mult Scler J Exp Transl Clin. 2021;7:20552173211049170.","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"434_CR65","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s11095-007-9502-2","volume":"25","author":"M Hammarlund-Udenaes","year":"2008","unstructured":"Hammarlund-Udenaes M, Frid\u00e9n M, Syv\u00e4nen S, Gupta A. On the rate and extent of drug delivery to the brain. Pharm Res. 2008;25:1737\u201350.","journal-title":"Pharm Res"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-023-00434-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-023-00434-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-023-00434-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T10:08:06Z","timestamp":1700906886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-023-00434-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,28]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["434"],"URL":"https:\/\/doi.org\/10.1007\/s40268-023-00434-6","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,28]]},"assertion":[{"value":"11 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was partially supported by the grant projects of the Ministry of Health of the Czech Republic (FN HK 00179906) and by Charles University in Prague, Czech Republic (PROGRES Q40\/15).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}